Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 29 of 29 results for ranibizumab

  1. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  2. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...

    Research recommendation
    Published
    9 June 2015

  3. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema...

    Research recommendation
    Published
    9 June 2015

  4. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA305

  5. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

    Technology appraisal guidance
    Published
    27 November 2013
    View recommendations

    Sections for TA298

  6. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  7. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

    Technology appraisal guidance
    Published
    22 May 2013
    View recommendations

    Sections for TA283

  8. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular oedema in adults.

    Technology appraisal guidance
    Last updated
    1 May 2012
    View recommendations

    Sections for TA155

  9. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Technology appraisal guidance
    Published
    30 November 2011

  10. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  11. Limited macular translocation for wet age-related macular degeneration (IPG339)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

    Interventional procedures guidance
    Published
    19 May 2010
    View recommendations

    Sections for IPG339

  12. Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]

    In development [GID-TA10879] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development